Alexander_Gutmans

Versant Ventures launches Cimeio Therapeutics with USD 50m Series A

Versant Ventures debut Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies. Versant has made a USD 50m Series A commitment to Cimeio, which is the most recent start-up to emerge from the firm’s Ridgeline Discovery Engine in Basel, Switzerland.

Cimeio’s initial focus is on a novel approach to hematopoietic stem cell (HSC) transplants and adoptive cell therapy (ACT). HSC transplants are the only curative treatments for certain debilitating and life-threatening diseases, but many patients are ineligible due to the intensive chemotherapy and radiation conditioning required. Cimeio seeks to transform HSC transplant and ACT eligibility and outcomes with its cell-shielding technology and precisely paired immunotherapies.

Walder Wyss advises Versant Ventures in connection with the launch of Cimeio Therapeutics. The team includes partner Alexander Gutmans (transaction/m&a & venture capital, pictured), associate Karina Tschon (transaction/m&a & venture capital), senior associate Michelle Bruni (tax and transaction/m&a), associate Lucas Maurer (transaction/m&a & venture capital) and associate Bojan Momic (employment).

From the other side, VISCHER advised Cimeo Therapeutics in connection with its launch and first financing. The team included Matthias Staehelin and Vincent Reardon (both Corporate).

Suzan Abdien Hago Taha

SHARE